• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » 3M’s V.A.C. Therapy hits 2,000 medical journal studies mark

3M’s V.A.C. Therapy hits 2,000 medical journal studies mark

October 14, 2022 By Sean Whooley

3M V.A.C. Therapy
V.A.C. Therapy. [Image from 3M]
3M (NYSE:MMM) Healthcare’s Medical Solutions Division announced the surpassing of 2,000 published studies for its V.A.C. Therapy.

Maplewood, Minnesota-based 3M’s V.A.C. delivers negative pressure wound therapy (NPWT). The company said it’s the only NPWT tech to hit the milestone of 2,000 published, peer-reviewed medical journal studies.

According to a news release, V.A.C. therapy accounts for more than 75% of published NPWT clinical evidence.

“Clinical evidence has always been a foundational element to establishing credibility for V.A.C. Therapy and our NPWT products in the wound care community,” said Dr. Ronald Silverman, M.D., 3M Health Care SVP of clinical affairs and CMO. “Published studies have also helped to promote adoption of NPWT and spur therapy innovations, including 3M Prevena therapy for incision management, 3M Veraflo therapy for instillation therapy for open wounds, 3M AbThera open abdomen negative pressure therapy.

“Our team members in the field are also actively engaged with wound care experts worldwide, working right alongside clinicians to observe the changing nature of wound care and gather feedback about our products, which helps us identify opportunities for innovation.”

More about V.A.C. therapy

V.A.C. therapy operates across a spectrum of healthcare settings today, 3M said. Its uses range from acute care facilities to ambulatory surgical centers, assisted living facilities and patient homes.

In the U.S., V.A.C. therapy features 24/7 remote therapy monitoring to support adherence. 3M added to its NPWT portfolio with its first-ever silicone-acrylic hybrid drape. The company designed the 3M Dermatac drape for easy clinician use while it remains gentle on the patient skin.

“Today’s wound care patients are often sicker and have more comorbidities, making their wounds more complex to treat and increasing the demands on clinicians’ time,” said Silverman. “3M strives to provide a robust tool selection to address clinicians’ unique wound care needs and make our products easier to use to help save their valuable time — and ultimately, help transform outcomes and improve lives for wound care patients.”

Filed Under: Business/Financial News, Clinical Trials, Featured, News Well, Wound Care Tagged With: 3m, 3M Health Care

More recent news

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Apreo Health emerges from stealth with positive data for lung scaffold
  • Tivic adds new vagus nerve stim patent
  • Study backs Teleflex stapler for reducing post-op GERD rates

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy